Síndrome de Sotos: nueva mutación «sin sentido» del gen NSD1 que presenta cutis laxa neonatal / Sotos syndrome: a novel nonsense mutation in nsd1 gene, presenting with neonatal cutis laxa

El síndrome de Sotos se caracteriza por sobrecrecimiento con facies peculiar, macrocefalia, talla alta y alteraciones del desarrollo psicomotor. Presentamos a un paciente de 20 meses de edad con diagnóstico confirmado por genética molecular con detección de mutación nonsense en el gen NSD1 no descrita previamente, exhibiendo cutis laxa como la característica fenotípica más llamativa en el periodo neonatal. Esta asociación se había descrito previamente en 3 pacientes con diagnóstico clínico de síndrome de Sotos sin diagnóstico molecular confirmatorio. En nuestro paciente, la presencia de cutis laxa llevó al diagnóstico diferencial con los defectos congénitos de glucosilación. En el seguimiento posnatal presentó una somatometría con perímetro cefálico y talla mayores de p97 (cercano a p50 al nacimiento), junto con el desarrollo de rasgos fenotípicos característicos del síndrome de Sotos durante los primeros meses de vida, los que proporcionaron la clave para el diagnóstico clínico y la investigación molecular (AU)

Sotos syndrome is an overgrowth condition characterized by facial gestalt, macrocephaly, excessive height, and different degrees of developmental delay. We report the case of a 20-month-old boy with a confirmatory molecular study, showing a novel nonsense mutation in NSD1 gene, presenting cutis laxa as the main phenotypic trait in the neonatal period. This association has been previously described in 3 patients with a clinical diagnosis of Sotos syndrome, without confirmatory molecular analysis. Our patient was tested for congenital disorders of glycosilation as part of the cutis laxa differential diagnosis. During the postnatal follow-up period the head circumference and height became greater than 97th percentile (having been close to the 50th in the newborn period). These facts and the progressive development of characteristic phenotypic features of Sotos syndrome during the first months of life gave us the clue for the clinical diagnosis and the molecular investigation (AU)

[Sotos syndrome: a novel nonsense mutation in NSD1 gene, presenting with neonatal cutis laxa]. / Síndrome de Sotos: nueva mutación «sin sentido¼ del gen NSD1 que presenta cutis laxa neonatal.

Sotos syndrome is an overgrowth condition characterized by facial gestalt, macrocephaly, excessive height, and different degrees of developmental delay. We report the case of a 20-month-old boy with a confirmatory molecular study, showing a novel nonsense mutation in NSD1 gene, presenting cutis laxa as the main phenotypic trait in the neonatal period. This association has been previously described in 3 patients with a clinical diagnosis of Sotos syndrome, without confirmatory molecular analysis. Our patient was tested for congenital disorders of glycosilation as part of the cutis laxa differential diagnosis. During the postnatal follow-up period the head circumference and height became greater than 97(th) percentile (having been close to the 50(th) in the newborn period). These facts and the progressive development of characteristic phenotypic features of Sotos syndrome during the first months of life gave us the clue for the clinical diagnosis and the molecular investigation.

Valor del examen de la placenta. A propósito de un caso de meningitis neonatal / The importance of placental examinational. Apropos of a case of neonatal meningitis

No disponible

No disponible

[Randomized multi-center trial of the administration of erythropoietin in anemia of prematurity]. / Estudio multicéntrico aleatorizado de administración de eritropoyetina en la anemia de la prematuridad.

OBJECTIVES: The purpose of this study was to test the therapeutic effect of human recombinant erythropoietin (rH-EPO) on anemia of prematurity. MATERIAL AND METHODS: Fifty-eight preterm infants less than 34 weeks of gestational age from three different hospitals were studied. Transfusional policies were similar in all three centers. Infants with ABO or Rh incompatibility were excluded. At 28 days after birth, 28 infants (48.3%) had hemoglobin levels under 10.5 g/dL and were randomized to receive rH-EPO or standard care. Those infants ascribed to the treatment group received 200 U/kg of body weight of rH-EPO subcutaneously once a day, three days a week for 4 weeks together with oral supplements of ferrous sulfate at a dosage of 4 mg/kg/day. Both groups received daily doses of 50 micrograms of folic acid and 5U of vitamin E per os. Erythropoietin and ferritin were determined at randomization and at 60 days of age. Hemoglobin, reticulocytes, leucocytes, granulocytes and platelets were measured once a week, from the beginning of the treatment until 60 days of age. RESULTS: At randomization into treatments, there were no significant differences between the groups with respect to weight, gestational age, hemoglobin (9.42 +/- 0.73 vs 9.26 +/- 0.68 g/dL), reticulocytes (61.7 +/- 32.2 vs 68.0 +/- 61.0 x 10(9)/L), ferritin, EPO1 leucocytes or platelets. At 60 days of age, the treatment group showed higher hemoglobin values (10.5 +/- 1.73 vs 9.1 +/- 1.0 g/dL, p < 0.05). There were no significant differences between reticulocyte counts (176.4 +/- 91.1 vs 112.6 +/- 85.0 x 10(9)/L), granulocytes (2,351 +/- 868 vs 2,075 +/- 856 x 10(9)/L), platelets (400 +/- 138 vs 316 +/- 164 x 10(9)/L) or ferritin (209 +/- 177 vs 393 +/- 328 micrograms/mL). Of the infants in the nontreated group, 13.3% received blood transfusions between 30 and 60 days of age, while only 6.7% of the treatment group did (p = 0.31). DISCUSSION: We have been able to find 11 controlled studies in the medical literature which deal with the clinical usage of rH-EPO in newborns. Six use the hormone in an early phase and 5 in a posterior one. Our study should be included in the later and, as happens in most of them, demonstrates the efficacy of rH-EPO in the treatment of late anemia of the preterm newborn as shown by an increment in the hemoglobin levels and a trend towards the diminution in the use of blood transfusions. We have not observed substantial adverse effects.

[Value of the Coombs test in ABO incompatibility]. / Valor del test de Coombs en la incompatibilidad ABO.

We studied the ABO haemolytic disease of the newborn in our neonatal unit to consider their serological aspects and clinical importance. 21% of all pregnancies were ABO incompatibles. The direct antiglobulin test was positive in 46 (11.3%) of them. The Elution was positive in all the newborns with direct antiglobulin test positive (Cd+). The anti-A o anti-B antibodies concentration in mothers was higher than 1/128 in 38 (84%). The C3d complement fraction was activated in two newborns. The infants Cd+ were born to group O mothers in all cases, and nobody was premature. Twelve (26%) of Cd+ presented jaundice which need phototherapy, and one moreover exchange transfusion. The direct antiglobulin test is very useful for detect the liable newborns of serious jaundice; therefore, we thing that is suitable to make this test in infants born to group O mothers. The newborns Cd+ did not have significant anemia at first three months of life.

[Transient neonatal pustular melanosis]. / Melanosis pustular transitoria neonatal.

Ten newborn infants with transient neonatal pustular melanosis are reported. The incidence (0.59%), the most noticeable clinical aspects and the differential diagnosis are pointed out. We report with special emphasis the presence of eosinophils in the smears from skin lesions. The authors think that transient neonatal pustular melanosis and erythema toxicum neonatorum are, probably, two different clinical expressions of the same entity.

[Pulmonary sequestration. Apropos of 10 cases]. / Secuestro pulmonar. A propósito de diez casos.

Pulmonary sequestration is a congenital anomaly in which an aberrant systemic artery arising from the thoracic or abdominal aorta supplies part of the lung, usually the lower lobes. The sequestrates part of the lung may be anatomically included in the substance of the lobe (intralobar) or may be separate from the other lobes, being contained within its own pleural investment (extralobar). The cases of ten patients with sequestration of the lung seen during a seven-year period are reviewed, with special consideration of their clinical and radiographic findings. Emphasis is made on the differences of our cases with those of the literature: 1) Eighty per cent of the patients had previous symptoms; 2) The intra/extralobar ratio was 1.5/1; 3) All intralobar sequestrations were indifferently localized in left or right lower lobes, and 4) Associated anomalies were present with the same incidence in the two classic forms.